作者
Gina A. Suh,Thomas P. Lodise,Pranita D. Tamma,Jane M. Knisely,Jose Alexander,Saima Aslam,Karen D. Barton,Erica Bizzell,Katherine M. C. Totten,Joseph L. Campbell,Benjamin K. Chan,Scott A. Cunningham,Katherine E. Goodman,Kerryl E. Greenwood‐Quaintance,Anthony D. Harris,Shayla Hesse,Anthony W. Maresso,Véronique Nussenblatt,David T. Pride,Michael J. Rybak,Zoë Sund,David van Duin,Daria Van Tyne,Robin Patel
摘要
Increasing antimicrobial resistance and medical device-related infections have led to a renewed interest in phage therapy as an alternative or adjunct to conventional antimicrobials. Expanded access and compassionate use cases have risen exponentially but have varied widely in approach, methodology, clinical situations in which phage therapy might be considered, dosing, route of administration, and outcomes.